Abstract
BackgroundThis study searched for immune-related long noncoding RNAs (lncRNAs) to predict the prognosis of patients with cervical cancer.MethodWe obtained immunologically relevant lncRNA expression profiles and clinical follow-up data from cervical cancer patients from The Cancer Genome Atlas database and the Molecular Signatures Database. Cervical cancer patients were randomly divided into a training group, testing group and combined group. The immune prognostic signature was constructed by Least Absolute Shrinkage and Selection Operator Cox regression, prognosis was analyzed by Kaplan–Meier curves between different groups, and the accuracy of the prognostic model was assessed by receiver operating characteristic-area under the curve (ROC-AUC) analysis.ResultsA six-lncRNA immune prognostic signature (LIPS) was constructed to predict the prognosis of cervical cancer. The six lncRNAs are as follows: AC009065.8, LINC01871, MIR210HG, GEMIN7-AS1, GAS5-AS1, and DLEU1. A ROC-AUC analysis indicated that the model could predict the prognosis of cervical cancer patients in different subgroups. A Kaplan–Meier analysis showed that patients with high risk scores had a poor prognosis; these results were equally meaningful in the subgroup analyses. Risk scores differed depending on the clinical pathology and tumor grade and were independent risk factors for cervical cancer prognosis. Gene set enrichment analysis revealed an association between the LIPS and the immune response, Wnt signaling pathway, and TGF beta signaling pathway.ConclusionOur study shows that the six-LIPS can predict the prognosis of cervical cancer and contribute to decisions regarding the immunotherapeutic strategy.
Highlights
Cervical cancer is one of the main causes of death in females
The results showed that the prognostic model consisting of 6 long noncoding RNAs (lncRNAs) could predict prognosis, and the following formula was used to calculate the risk score: Rscore = −0.46211 × ExpAC009065.8 +
The AUCROC value for 1-year survival was 0.789, the AUC-receiver operating characteristic (ROC) value for 3-year survival was 0.697, and the AUC-ROC value for 5-year survival was 0.741. These results show that the lncRNA immune prognostic signature (LIPS) can be a good indicator of the prognosis of cervical cancer
Summary
Cervical cancer is one of the main causes of death in females. screening and vaccination programs have been expanded, the number of new cases of cervical cancer has continued to increase, which means that cervical cancer is a major public health concern (Arbyn et al, 2020). The conventional treatment of cervical cancer includes radiotherapy, chemotherapy and surgery, but patients at advanced stages are prone to developing radiotherapy and chemotherapy resistance (Seol et al, 2014). It is necessary to identify new prognostic markers and treatment options for cervical cancer to improve the survival of cervical cancer patients. The response of cervical cancer to the immune system affects tumor progression and treatment (Chen R. et al, 2019). Cytokines secreted by immune cells in the microenvironment inhibit the development of cervical cancer (Chauhan et al, 2019). The multi-immune infiltration cell signature in the tumor microenvironment has been shown to predict the prognosis of cervical cancer (Wang J. et al, 2019). This study searched for immune-related long noncoding RNAs (lncRNAs) to predict the prognosis of patients with cervical cancer
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
